Mayo Collaborative Services v. Prometheus Laboratories, Inc.

Target entity: Mayo Collaborative Services v. Prometheus Laboratories, Inc.
Context triple: [Association for Molecular Pathology v. Myriad Genetics, Inc., relatedTo, Mayo Collaborative Services v. Prometheus Laboratories, Inc.]

• A. Association for Molecular Pathology v. Myriad Genetics, Inc.
  Association for Molecular Pathology v. Myriad Genetics, Inc. is a landmark 2013 U.S. Supreme Court case that held naturally occurring human genes cannot be patented, reshaping the legal landscape for biotechnology and genetic testing.
• B. In re Chakrabarty
  In re Chakrabarty is a landmark 1980 U.S. Supreme Court case that held genetically engineered living organisms can be patented, significantly shaping modern biotechnology patent law.
• C. In re Diehr
  In re Diehr is a landmark 1981 U.S. Supreme Court patent law decision that clarified the patent eligibility of computer-implemented inventions under 35 U.S.C. § 101.
• D. Leahy–Smith America Invents Act
  The Leahy–Smith America Invents Act is a 2011 U.S. patent reform law that overhauled the patent system, including shifting to a first-inventor-to-file regime and creating new post-grant review procedures.
• E. Cohen–Boyer recombinant DNA patents
  The Cohen–Boyer recombinant DNA patents were foundational biotechnology patents that covered key methods for creating recombinant DNA, enabling modern genetic engineering and the biotechnology industry.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: Mayo Collaborative Services v. Prometheus Laboratories, Inc.
Target entity description: Mayo Collaborative Services v. Prometheus Laboratories, Inc. is a landmark 2012 U.S. Supreme Court case that limited the patentability of medical diagnostic methods by holding that laws of nature and their routine applications are not eligible for patent protection.

• A. Association for Molecular Pathology v. Myriad Genetics, Inc.
  Association for Molecular Pathology v. Myriad Genetics, Inc. is a landmark 2013 U.S. Supreme Court case that held naturally occurring human genes cannot be patented, reshaping the legal landscape for biotechnology and genetic testing.
• B. In re Chakrabarty
  In re Chakrabarty is a landmark 1980 U.S. Supreme Court case that held genetically engineered living organisms can be patented, significantly shaping modern biotechnology patent law.
• C. In re Diehr
  In re Diehr is a landmark 1981 U.S. Supreme Court patent law decision that clarified the patent eligibility of computer-implemented inventions under 35 U.S.C. § 101.
• D. Leahy–Smith America Invents Act
  The Leahy–Smith America Invents Act is a 2011 U.S. patent reform law that overhauled the patent system, including shifting to a first-inventor-to-file regime and creating new post-grant review procedures.
• E. Cohen–Boyer recombinant DNA patents
  The Cohen–Boyer recombinant DNA patents were foundational biotechnology patents that covered key methods for creating recombinant DNA, enabling modern genetic engineering and the biotechnology industry.
• F. None of above. chosen